725 related articles for article (PubMed ID: 30586620)
21. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy.
Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y
Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884
[TBL] [Abstract][Full Text] [Related]
22. Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
Dos Santos DMC; Rejeski K; Winkelmann M; Liu L; Trinkner P; Günther S; Bücklein VL; Blumenberg V; Schmidt C; Kunz WG; Von Bergwelt-Baildon M; Theurich S; Subklewe M
Haematologica; 2022 Sep; 107(9):2096-2107. PubMed ID: 35172565
[TBL] [Abstract][Full Text] [Related]
23. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
Front Immunol; 2022; 13():927153. PubMed ID: 35757715
[TBL] [Abstract][Full Text] [Related]
24. Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome.
Zheng N; Long Y; Bai Z; Li J; Wang H; Song DD; Liu HL; Shi JH; Zhao S
J Transl Med; 2024 Jan; 22(1):58. PubMed ID: 38221609
[TBL] [Abstract][Full Text] [Related]
25. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.
Zi FM; Ye LL; Zheng JF; Cheng J; Wang QM
Medicine (Baltimore); 2021 May; 100(19):e25786. PubMed ID: 34106613
[TBL] [Abstract][Full Text] [Related]
26. Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy.
Davis JA; Gaffney KJ; McGann M; Smith D; Edwards K; Baldino E; Bakos K; Butcher C; Greenwell B; Hess BT; Hashmi H
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e14-e18. PubMed ID: 36319568
[TBL] [Abstract][Full Text] [Related]
27. Management of CAR T-cell Related Toxicities: What did the Learning Curve Teach us so Far?
Murthy HS; Yassine F; Iqbal M; Alotaibi S; Moustafa MA; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):100-111. PubMed ID: 36395496
[TBL] [Abstract][Full Text] [Related]
28. Cytokine release syndrome: Who is at risk and how to treat.
Frey N
Best Pract Res Clin Haematol; 2017 Dec; 30(4):336-340. PubMed ID: 29156206
[TBL] [Abstract][Full Text] [Related]
29. Not so crystal clear: observations from a case of crystalline arthritis with cytokine release syndrome (CRS) after chimeric antigen receptor (CAR)-T cell therapy.
Chung SH; Hughes G; Koffman B; Turtle CJ; Maloney DG; Acharya UH
Bone Marrow Transplant; 2019 Apr; 54(4):632-634. PubMed ID: 30291306
[No Abstract] [Full Text] [Related]
30. Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models.
Chavez JC; Jain MD; Kharfan-Dabaja MA
Hematol Oncol Stem Cell Ther; 2020 Mar; 13(1):1-6. PubMed ID: 31202671
[TBL] [Abstract][Full Text] [Related]
31. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
Park JH; Romero FA; Taur Y; Sadelain M; Brentjens RJ; Hohl TM; Seo SK
Clin Infect Dis; 2018 Aug; 67(4):533-540. PubMed ID: 29481659
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy.
Gill J
Curr Cardiol Rev; 2023; 19(1):e230622206353. PubMed ID: 35747980
[TBL] [Abstract][Full Text] [Related]
33. Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome.
Pabst T; Joncourt R; Shumilov E; Heini A; Wiedemann G; Legros M; Seipel K; Schild C; Jalowiec K; Mansouri Taleghani B; Fux M; Novak U; Porret N; Zeerleder S; Bacher U
Exp Hematol; 2020 Aug; 88():7-14.e3. PubMed ID: 32673688
[TBL] [Abstract][Full Text] [Related]
34. Cytokine Release Syndrome after Chimeric Antigen Receptor Transduced T-Cell Therapy in Cancers: A Systematic Review.
Taheri S
Saudi J Kidney Dis Transpl; 2022 Nov; 33(6):795-823. PubMed ID: 38018721
[TBL] [Abstract][Full Text] [Related]
35. [CARs, CRS and neurotoxicity: severe complications after administration of immunotherapy : Essentials for intensivists].
Prinz J; d'Hargues Y; Gödel P; Shimabukuro-Vornhagen A; Kochanek M; Böll B
Med Klin Intensivmed Notfmed; 2020 Apr; 115(3):198-204. PubMed ID: 30547223
[TBL] [Abstract][Full Text] [Related]
36. An Overview of Cytokine Release Syndrome and Other Side Effects of CAR-T Cell Therapy.
Genoud V; Migliorini D
Praxis (Bern 1994); 2023; 112(3):189-193. PubMed ID: 36855881
[No Abstract] [Full Text] [Related]
37. Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia.
Zhang Y; Zhou F; Wu Z; Li Y; Li C; Du M; Luo W; Kou H; Lu C; Mei H
Front Immunol; 2022; 13():914959. PubMed ID: 35799791
[TBL] [Abstract][Full Text] [Related]
38. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
[TBL] [Abstract][Full Text] [Related]
39. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies.
Yang C; Nguyen J; Yen Y
J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230
[TBL] [Abstract][Full Text] [Related]
40. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.
Totzeck M; Michel L; Lin Y; Herrmann J; Rassaf T
Eur Heart J; 2022 May; 43(20):1928-1940. PubMed ID: 35257157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
